Raymond James Financial Inc. Makes New Investment in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Raymond James Financial Inc. purchased a new stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 79,044 shares of the biotechnology company’s stock, valued at approximately $707,000.

Other large investors have also recently modified their holdings of the company. Charles Schwab Investment Management Inc. increased its holdings in Astria Therapeutics by 2.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 322,576 shares of the biotechnology company’s stock valued at $2,884,000 after purchasing an additional 8,311 shares during the period. New York State Common Retirement Fund lifted its holdings in Astria Therapeutics by 67.0% during the 4th quarter. New York State Common Retirement Fund now owns 10,720 shares of the biotechnology company’s stock worth $96,000 after buying an additional 4,300 shares during the period. Rhumbline Advisers grew its position in shares of Astria Therapeutics by 2.3% in the 4th quarter. Rhumbline Advisers now owns 62,163 shares of the biotechnology company’s stock valued at $556,000 after buying an additional 1,381 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Astria Therapeutics in the 4th quarter valued at about $107,000. Finally, SG Americas Securities LLC increased its stake in shares of Astria Therapeutics by 51.3% in the fourth quarter. SG Americas Securities LLC now owns 21,296 shares of the biotechnology company’s stock valued at $190,000 after buying an additional 7,218 shares during the period. Institutional investors own 98.98% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ATXS shares. Citizens Jmp raised Astria Therapeutics to a “strong-buy” rating in a research note on Friday, January 31st. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research report on Tuesday, March 11th. Wedbush reaffirmed an “outperform” rating and issued a $28.00 price objective (up from $27.00) on shares of Astria Therapeutics in a research note on Wednesday, March 12th. Finally, JMP Securities assumed coverage on shares of Astria Therapeutics in a research note on Friday, January 31st. They set an “outperform” rating and a $26.00 target price for the company. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $26.60.

Astria Therapeutics Stock Performance

Shares of ATXS opened at $4.66 on Friday. The firm has a market cap of $262.98 million, a PE ratio of -2.23 and a beta of 0.68. Astria Therapeutics, Inc. has a 52-week low of $4.62 and a 52-week high of $12.92. The business’s 50 day moving average price is $6.58 and its two-hundred day moving average price is $8.93.

Astria Therapeutics (NASDAQ:ATXS) last released its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.01. Research analysts predict that Astria Therapeutics, Inc. will post -1.65 EPS for the current fiscal year.

Astria Therapeutics Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.